Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Monday's Featured Article A Fresh IPO That Long-Term Investors Shouldn't IgnoreReported by Jordan Chussler. Article Posted: 1/14/2026. 
At a Glance - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't dismiss every newly listed stock—some recent IPOs may merit a place in buy-and-hold portfolios. Gold Hoarding Could Send Gold EVEN HIGHER
Many are wondering why so many countries are frantically buying gold right now. The truth is that this is just the beginning of a much larger story... One that could send gold soaring to even bigger highs in the coming months. But the best way to cash in on gold's upside potential might surprise you. One firm says this stock (less than $50) could be the best way to get started. Strange New Catalyst for Gold ($5,000 Possible?) One biotechnology company in the healthcare sector that just went public could be such a candidate. Last Year's IPO Success Stories Last year provides strong examples of why newly public companies deserve a look—even from investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its nearly 359% gain early after listing on Nasdaq, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the notion that IPOs are all high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already boasts a market cap north of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has paid a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for similar success in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with targeting molecules that seek out specific cells (for example, cancer cells) to deliver localized doses of radiation, thereby minimizing harm to healthy tissue that can occur with conventional radiation therapies. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will approach $35 billion by 2030—a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant market. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts in 2025 slowed listings from the healthcare sector. Aktis Oncology, which debuted on Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million—one of the largest recent fundraising rounds for a biotech IPO. The company now carries a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes experienced drug developers and commercial leaders who have participated in bringing 14 currently FDA-approved products to market. At a program level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting significant industry support—most notably from Eli Lilly (NYSE: LLY). Per Reuters, Eli Lilly purchased $100 million of AKTS shares in the IPO. This investment builds on a 2024 partnership in which Lilly committed $60 million in cash and an equity investment to develop tumor-targeting radiopharmaceuticals, with potential milestone payments to Aktis that could exceed $1 billion. The significance of Eli Lilly's backing is notable. With a market cap around $1.01 trillion, Lilly is among the largest pharmaceutical companies by market value. Its net income rose nearly 109% year-over-year from 2023 to 2024, and the company is set to report Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS shares, the maker of Zepbound has a sizable financial interest in Aktis Oncology's success.
| 
